On October 28, 2019 Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, reported that the Company intends to release its operational highlights and financial results for the quarter ended September 30, 2019 on Monday, November 4, 2019, and to host a conference call the same day at 4:30 p.m. ET (Press release, Synthetic Biologics, OCT 28, 2019, View Source [SID1234549935]). The dial-in information for the call is as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

U.S. (toll free): 1-888-347-5280
International: +1 412-902-4280

Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at View Source." target="_blank" title="View Source." rel="nofollow">View Source An archived replay of the call will be available for approximately ninety (90) days at the same URL, View Source beginning approximately one hour after the call’s conclusion.

On October 28, 2019 Universal Health Services, Inc. (NYSE: UHS) reported that Steve Filton, Executive Vice President and Chief Financial Officer will present at the 2019 Wolfe Research Healthcare Conference in New York, New York on Wednesday, November 6, 2019 at 11:15am (ET) (Press release, Universal Health Services, OCT 28, 2019, View Source [SID1234549934]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available on the Company’s website (www.uhsinc.com). For those unable to listen to the live webcast, replays of the presentation will be available on the Company’s website for 90 days following the conference.

Headquartered in King of Prussia, PA, UHS has more than 87,000 employees and through its subsidiaries operates 354 inpatient acute care hospitals and behavioral health facilities and 40 outpatient and other facilities located in 37 states, Washington, D.C., Puerto Rico and the United Kingdom. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT). For additional information on the Company, visit our web site: View Source

On October 28, 2019 Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") reported financial results for the third quarter ended September 30, 2019 (Press release, Medpace, OCT 28, 2019, View Source [SID1234549933]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In the third quarter the business environment remained steady, and cancellations continued at normal levels"

Tweet this
"In the third quarter the business environment remained steady, and cancellations continued at normal levels," said August J. Troendle, President & Chief Executive Officer.

Third Quarter 2019 Financial Results

Revenue for the three months ended September 30, 2019 increased 20.6% to $216.2 million, compared to $179.3 million for the comparable prior-year period. On a constant currency organic basis, revenue for the third quarter of 2019 increased 21.0% compared to the third quarter of 2018.

Backlog as of September 30, 2019 grew 19.9% to $1.2 billion from $1.0 billion as of September 30, 2018. Net new business awards were $285.4 million, representing a net book-to-bill ratio of 1.32x for the third quarter of 2019, as compared to $227.6 million for the comparable prior-year period. The Company calculates the net book-to-bill ratio by dividing net new business awards by revenue.

For the third quarter of 2019, total direct costs were $152.1 million, compared to total direct costs of $124.0 million in the third quarter of 2018. Selling, general and administrative (SG&A) expenses were $29.1 million, compared to SG&A expenses of $18.6 million in the third quarter of 2018.

GAAP net income for the third quarter of 2019 was $24.0 million, or $0.63 per diluted share, versus GAAP net income of $19.3 million, or $0.52 per diluted share, for the third quarter of 2018. This resulted in a net income margin of 11.1% and 10.8% for the third quarter of 2019 and 2018, respectively.

EBITDA for the third quarter of 2019 decreased 6.4% to $34.8 million, or 16.1% of revenue, compared to $37.1 million, or 20.7% of revenue, for the comparable prior-year period. On a constant currency basis, EBITDA for the third quarter of 2019 decreased 8.0% from the third quarter of 2018.

Adjusted Net Income for the third quarter of 2019 increased 8.0% to $27.0 million compared to $25.0 million for the comparable prior-year period. Adjusted Net Income per diluted share for the third quarter of 2019 was $0.71, representing an increase of 6.0%, compared to Adjusted Net Income per diluted share of $0.67 for the comparable prior-year period.

A reconciliation of the Company’s non-GAAP financial measures, including EBITDA, EBITDA margin, Adjusted Net Income, and Adjusted Net Income per diluted share to the corresponding GAAP measures is provided below.

Balance Sheet and Liquidity

The Company’s Cash and cash equivalents were $79.3 million at September 30, 2019, and the Company generated $64.3 million in cash flow from operating activities during the third quarter of 2019.

Financial Guidance

The Company forecasts 2019 revenue in the range of $840.0 million to $860.0 million, representing growth of 19.2% to 22.1% over 2018 revenue of $704.6 million. GAAP net income for full year 2019 is forecasted in the range of $94.9 million to $99.7 million. Additionally, full year 2019 EBITDA is expected in the range of $144.0 million to $150.0 million.

Based on forecasted 2019 revenue of $840.0 million to $860.0 million and GAAP net income of $94.9 million to $99.7 million, diluted earnings per share (GAAP) is forecasted in the range of $2.51 to $2.64. Adjusted Net Income for 2019 is forecasted in the range of $107.2 million to $112.0 million, compared to Adjusted Net Income of $95.5 million for 2018. Furthermore, Adjusted Net Income per diluted share for 2019 is expected in the range of $2.85 to $2.97 per share.

Conference Call Details

Medpace will host a conference call at 9:00 a.m. ET, Tuesday, October 29, 2019, to discuss its third quarter 2019 results.

To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 7668623.

To access the conference call via webcast, visit the "Investors" section of Medpace’s website at medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A supplemental slide presentation will also be available at the "Investors" section of Medpace’s website prior to the start of the call.

A recording of the call will be available at 12:00 p.m. ET on Tuesday, October 29, 2019 until 12:00 p.m. ET on Tuesday, November 12, 2019. To hear this recording, dial 855-859-2056 (domestic) or 404-537-3406 (international) using the passcode 7668623.

On October 28, 2019 Molecular Targeting Technologies, Inc. (MTTI) reported that the NIBIB (an Institute within the National Institutes of Health (NIH)) has granted MTTI an exclusive worldwide license to commercialize patented technology invented by Drs. Xiaoyuan Chen and Orit Jacobson (Press release, Molecular Targeting Technologies, OCT 28, 2019, View Source [SID1234549932]). This patent portfolio covers a targeted radiotherapeutic 177Lu-EBRGD for integrin expressing cancers including treating Glioblastoma multiforme (GBM) and Non-Small Cell Lung cancer (NSCLC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The key feature of this technology is the incorporation of a derivative of Evans Blue into RGD peptide radiopharmaceutical which binds to both albumin and integrin thus extends residence time, enabling smaller and less frequent dosing.

"Integrin is highly expressed in both tumor blood vessels and tumor cells in glioblastoma patients. Based on our study using Ga-68 PRGD2, we believe that Lu-177 EBRGD could be the next innovative radiotherapeutic in treating GBM," said Deling Li, MD. Vice Director of Brain Tumor and International Translational Molecular Imaging Center for Brain Tumor (ITMIC-BT), Beijing Tiantan Hospital.

"We are privileged to receive the exclusive global license from NIH," said Chris Pak, President & CEO of MTTI. "Currently, we are already advancing NIH’s EBTATE for treating neuroendocrine tumors and we look forward to moving EBRGD to tackle hard-to-treat cancers such as GBM and NSCLC."

MTTI is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of disease. More information: www.mtarget.com.

*Chen H et al. Novel "Add-On" Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents. J Nucl Med 2017;58:590-597.

On October 28, 2019 KSQ Therapeutics, a biotechnology company using CRISPR technology to enable the company’s powerful discovery engine to achieve higher probabilities of success in drug development, reported two upcoming presentations at leading scientific immuno-oncology congresses (Press release, KSQ Therapeutics, OCT 28, 2019, View Source [SID1234549931]). The data demonstrate the capabilities of the company’s proprietary CRISPRomics discovery engine, which allows genome-scale, in vivo validated, unbiased drug discovery.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There is a significant need for next-generation immuno-oncology therapies as the majority of cancer patients today experience an insufficient response to PD-1/PD-L1 therapies. The data we will be sharing demonstrate the potential of our CRISPRomics discovery platform to systematically identify and validate new cancer therapies for patients with PD-1 refractory solid tumors," said Frank Stegmeier, Ph.D., Chief Scientific Officer at KSQ Therapeutics. "KSQ was founded on the premise that CRISPR-enabled functional genomics can improve on current approaches to drug discovery and, taken together, these poster presentations describing the output of our genome-scale in vivo T-cell screens show that our platform can do this with a high degree of precision and quality, pointing the direction towards promising avenues of drug development."

Presentations include:

At the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper): Comprehensive identification of novel therapeutic targets for treatment of PD-1 resistant solid tumors via a genome-scale CRISPR/Cas9 in vivo T-cell screen – Poster # C101 – Tuesday, October 29 – 3:30-4:00 p.m. – Level 2 Hall D
At the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 34th Annual Meeting: An immune-CRISPRomics platform enabling genome-scale and pair-wise combination in vivo T-cell function screens enables comprehensive identification of novel therapeutic targets – Poster # P550 – Saturday, November 9 – 12:35–2:05 p.m. and 7:00-8:35 p.m.